

# Sumanta K Pal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3215092/publications.pdf>

Version: 2024-02-01

383  
papers

15,883  
citations

19636

61  
h-index

22147

113  
g-index

386  
all docs

386  
docs citations

386  
times ranked

18076  
citing authors

#	ARTICLE	IF	CITATIONS
1	Collecting duct carcinoma of the kidney: diagnosis and implications for management. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 525-536.	0.8	8
2	A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clinical Genitourinary Cancer, 2022, 20, 1-10.	0.9	4
3	Prostate Cancer Characteristics and Outcomes after Prostatectomy in Asian-American Men. Clinical Genitourinary Cancer, 2022, 20, 92-92.e6.	0.9	2
4	Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 35-42.	0.9	5
5	Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. Future Oncology, 2022, 18, 21-33.	1.1	5
6	Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 25-36.	0.8	14
7	Cytoreductive Nephrectomy in 2021: Obsolete. European Urology Open Science, 2022, 36, 44-46.	0.2	8
8	Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research, 2022, 28, 1353-1362.	3.2	10
9	A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncology, 2022, 18, 1185-1198.	1.1	10
10	Tumor genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation (UCS) compared to pure urothelial carcinoma (UC).. Journal of Clinical Oncology, 2022, 40, 553-553.	0.8	0
11	Intestinal microbiome associated with development of grade 3/4 adverse in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (N/I) and probiotic support: Results from a phase Ib study.. Journal of Clinical Oncology, 2022, 40, 374-374.	0.8	0
12	First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2022, 40, 317-317.	0.8	2
13	Long-term PFS from TIVO-3: Tivozanib (TIVO) versus sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC.. Journal of Clinical Oncology, 2022, 40, 362-362.	0.8	3
14	The association of FDG PET/CT and NaF PET/CT with survival outcomes in patients (pts) with metastatic genitourinary malignancies (mGU) treated with cabozantinib + nivolumab +/- ipilimumab (CaboNivo +/-) Tj ETQq0 00sgBT /Overlock 10	0.8	0
15	Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer.. Journal of Clinical Oncology, 2022, 40, 561-561.	0.8	0
16	Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).. Journal of Clinical Oncology, 2022, 40, 310-310.	0.8	1
17	SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.. Journal of Clinical Oncology, 2022, 40, TPS402-TPS402.	0.8	2
18	Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: A randomized phase Ib study and the evolution of the functionality of microbial communities with treatment.. Journal of Clinical Oncology, 2022, 40, 371-371.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Prospective assessment of a smartphone-app based mindfulness program for patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2022, 40, 324-324.	0.8	2
20	Association of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2022, 40, 372-372.	0.8	2
21	Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy.. Journal of Clinical Oncology, 2022, 40, 336-336.	0.8	1
22	Characterization of aberrant alternative splicing landscape in patients with renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2022, 40, 386-386.	0.8	1
23	Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine, 2022, 28, 704-712.	15.2	181
24	Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. European Urology, 2022, 82, 283-292.	0.9	14
25	Characteristics associated with common reasons to pursue genomic profiling among patients with metastatic genitourinary cancers.. Journal of Clinical Oncology, 2022, 40, 327-327.	0.8	0
26	Shining a light on the psychological burden of cancer. Nature Medicine, 2022, 28, 637-638.	15.2	1
27	Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Medicine, 2022, 11, 21-27.	1.3	15
28	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research, 2022, 28, 831-839.	3.2	12
29	Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions. Cancers, 2022, 14, 2049.	1.7	7
30	Quality of Life Data in CheckMate 274: Does It Move the Needle?. European Urology Oncology, 2022, , .	2.6	0
31	Targeting <i>FGFR3</i> alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncology, 2022, 18, 2599-2614.	1.1	10
32	How to Treat Renal Cell Carcinoma. JACC: CardioOncology, 2022, 4, 271-275.	1.7	3
33	Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncology, The, 2022, 23, 899-909.	5.1	26
34	Defining "platinum-ineligible" patients with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2022, 40, 4577-4577.	0.8	17
35	EVEREST: Everolimus for renal cancer ensuing surgical therapy" A phase III study (SWOG S0931), Tj ETQq1 1 0.784314 rgBT /Overl	0.8	29
36	A phase I trial to evaluate the biologic effect of CBM588 ( <i>Clostridium butyricum</i> ) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2022, 40, TPS4606-TPS4606.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.. Journal of Clinical Oncology, 2022, 40, 4531-4531.	0.8	3
38	Maturation of overall survival (OS) in TIVO-3 with long-term follow-up.. Journal of Clinical Oncology, 2022, 40, 4557-4557.	0.8	2
39	Activity of tivozanib in non-clear cell renal cell carcinoma (nccRCC): Subgroup analysis from a phase 2 randomized discontinuation trial.. Journal of Clinical Oncology, 2022, 40, 4542-4542.	0.8	0
40	Phase Ib study of avelumab and novel AXL inhibitor avb-S6-500 in patients with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2022, 40, 4579-4579.	0.8	0
41	TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.. Journal of Clinical Oncology, 2022, 40, TPS4605-TPS4605.	0.8	2
42	Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity.. Journal of Clinical Oncology, 2022, 40, 4510-4510.	0.8	0
43	Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).. Journal of Clinical Oncology, 2022, 40, 4554-4554.	0.8	0
44	Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2022, 40, 4555-4555.	0.8	0
45	COVID-19 and financial toxicity in patients with renal cell carcinoma. World Journal of Urology, 2021, 39, 2559-2565.	1.2	11
46	Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma. European Urology Focus, 2021, 7, 1355-1362.	1.6	9
47	A drug delivery perspective on intratumoral-immunotherapy in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 338-345.	0.8	2
48	Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. European Urology Oncology, 2021, 4, 297-300.	2.6	18
49	Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma. Cancer Medicine, 2021, 10, 79-86.	1.3	36
50	Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status. Cancer, 2021, 127, 354-358.	2.0	19
51	Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. Prostate Cancer and Prostatic Diseases, 2021, 24, 448-456.	2.0	0
52	Association between hospital anxiety and depression scale and problemâ€related distress in patients with cancer in a Brazilian private institution. Psycho-Oncology, 2021, 30, 296-302.	1.0	2
53	Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. Clinical Cancer Research, 2021, 27, 1391-1398.	3.2	20
54	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 78-86.	3.2	154

#	ARTICLE	IF	CITATIONS
55	Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100325.	0.7	24
56	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , 2021, 4, e2021869.	2.8	104
57	Radiomic features of renal cell carcinoma primary and metastatic sites as predictors of TERT and BAP1 mutations.. <i>Journal of Clinical Oncology</i> , 2021, 39, 282-282.	0.8	1
58	Illustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data.. <i>Journal of Clinical Oncology</i> , 2021, 39, 347-347.	0.8	0
59	Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 270-270.	0.8	8
60	A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS190-TPS190.	0.8	5
61	First assessment of the stool mycobiome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving targeted therapy (TT) or immunotherapy (IO).. <i>Journal of Clinical Oncology</i> , 2021, 39, 337-337.	0.8	0
62	Q-TWIST analysis of tivozanib (T) versus sorafenib (S) in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 298-298.	0.8	1
63	Associations between plasma cytokine levels and gut microbiota composition in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 351-351.	0.8	0
64	A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. <i>Lancet, The</i> , 2021, 397, 695-703.	6.3	146
65	Real-world prevalence of homologous recombination repair gene (BRCA1/2 and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA).. <i>Journal of Clinical Oncology</i> , 2021, 39, 256-256.	0.8	0
66	Wnt/ $\beta$ -Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma. <i>Cancers</i> , 2021, 13, 889.	1.7	24
67	CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS370-TPS370.	0.8	18
68	Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).. <i>Journal of Clinical Oncology</i> , 2021, 39, 307-307.	0.8	9
69	Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA).. <i>Journal of Clinical Oncology</i> , 2021, 39, 162-162.	0.8	0
70	Distinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 352-352.	0.8	0
71	Comprehensive genomic profiling of matched primary prostate cancer tissue and cell-free DNA (cfDNA) to assess ontogeny of BRCA1/BRCA2 mutations.. <i>Journal of Clinical Oncology</i> , 2021, 39, 166-166.	0.8	0
72	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. <i>Future Science OA</i> , 2021, 7, FSO662.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.. <i>Journal of Clinical Oncology</i> , 2021, 39, 314-314.	0.8	1
74	Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. , 2021, 9, e002009.		21
75	A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. <i>Investigational New Drugs</i> , 2021, 39, 1324-1334.	1.2	2
76	Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 205, 709-717.	0.2	7
77	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). <i>Cancer</i> , 2021, 127, 2204-2212.	2.0	32
78	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 313-319.	12.5	103
79	Renal Cell Carcinoma With Urinary Bladder Metastasis: A Case Report With Metachronous Genomic Analyses. <i>JCO Precision Oncology</i> , 2021, 5, 557-560.	1.5	1
80	Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. <i>European Urology Oncology</i> , 2021, 4, 170-179.	2.6	28
81	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). <i>Oncologist</i> , 2021, 26, 560-e1103.	1.9	6
82	Systemic therapy and COVID19: Immunotherapy and chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 213-220.	0.8	5
83	Emotional problemâ€related distress screening and its prevalence by cancer type: Assessment by patients' characteristics and level of assistance requested. <i>Psycho-Oncology</i> , 2021, 30, 1332-1338.	1.0	9
84	Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 125-134.	0.9	4
85	ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready?. <i>JCO Precision Oncology</i> , 2021, 5, 767-770.	1.5	6
86	Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group. <i>JCO Global Oncology</i> , 2021, 7, 671-685.	0.8	3
87	TIVO-3: Durability of response and updated overall survival of tivozanib versus sorafenib in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4546-4546.	0.8	2
88	TIVO-3: Age-related tolerability outcomes of tivozanib versus sorafenib in metastatic relapsed or refractory renal cell carcinoma, a subgroup analysis of the TIVO-3 clinical trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16553-e16553.	0.8	0
89	First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4513-4513.	0.8	12
90	Bridging the gaps between tertiary and community care networks: Results from a southern California survey research analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1538-1538.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. <i>European Urology Oncology</i> , 2021, 4, 893-903.	2.6	31
92	Biomarker approach harnessed in trials of personalized medicine for bladder cancer. <i>Nature Medicine</i> , 2021, 27, 761-763.	15.2	5
93	Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16515-e16515.	0.8	1
94	Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4567-4567.	0.8	1
95	Treatment outcomes in renal cell carcinoma patients with metastases to the pancreas and other sites.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4557-4557.	0.8	0
96	Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4503-4503.	0.8	27
97	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1454-1461.	1.9	6
98	Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic. <i>Kidney Cancer</i> , 2021, 5, 73-78.	0.2	1
99	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. <i>Cancers</i> , 2021, 13, 2776.	1.7	9
100	Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4807-4813.	3.2	9
101	Learning from BISCAY: The future of biomarker-based trial design in bladder cancer. <i>Cancer Cell</i> , 2021, 39, 910-912.	7.7	4
102	Chemoimmunotherapy in urothelial cancer: concurrent or sequential?. <i>Lancet Oncology</i> , The, 2021, 22, 894-896.	5.1	4
103	Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. <i>Cancer Medicine</i> , 2021, 10, 5671-5680.	1.3	2
104	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. <i>Cancer</i> , 2021, 127, 3957-3966.	2.0	11
105	Editorial Comment. <i>Journal of Urology</i> , 2021, 206, 251-251.	0.2	0
106	Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 1536.	3.4	28
107	Recall of Genomic Testing Results Among Patients with Cancer. <i>Oncologist</i> , 2021, 26, e2302-e2305.	1.9	8
108	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 354-361.	0.9	5

#	ARTICLE	IF	CITATIONS
109	Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 912-920.	1.0	0
110	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 904.	1.1	10
111	Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. , 2021, 9, e002931.		18
112	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. <i>Cancers</i> , 2021, 13, 4951.	1.7	19
113	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3725-3736.	0.8	69
114	Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , 2021, 10, 1212-1221.	1.3	22
115	Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1339-1346.	1.6	58
116	Fighting the “tobacco epidemic” – A call to action to identify Targeted Intervention Points (TIPs) for better counseling patients with urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 793-796.	0.8	2
117	Mutations in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 763-773.	0.8	58
118	The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. <i>Oncologist</i> , 2020, 25, e39-e47.	1.9	13
119	Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 724-726.	0.5	2
120	Association between chemotherapy toxicity risk scores and physical symptoms among older Brazilian adults with cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 280-283.	0.5	5
121	Patient-reported Outcome Measures in Metastatic Urinary Cancers. <i>European Urology Focus</i> , 2020, 6, 26-30.	1.6	11
122	Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How. <i>European Urology</i> , 2020, 77, 22-23.	0.9	4
123	Squamous Transformation of Prostate Adenocarcinoma: A Report of Two Cases With Genomic Profiling. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e289-e292.	0.9	7
124	Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 126, 1-10.	1.3	19
125	Distress and Quality of Life Among Patients with Advanced Genitourinary Cancers. <i>European Urology Focus</i> , 2020, 6, 1150-1154.	1.6	9
126	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. <i>Lancet Oncology</i> , The, 2020, 21, 95-104.	5.1	160



#	ARTICLE	IF	CITATIONS
127	Peroxisome proliferator-activated receptor gamma controls prostate cancer cell growth through AR-dependent and independent mechanisms. <i>Prostate</i> , 2020, 80, 162-172.	1.2	11
128	Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 193-202.	0.6	16
129	Switch maintenance therapy for advanced bladder cancer: A paradigm shift in 2020. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100202.	0.7	0
130	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 916-924.	0.9	18
131	Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis. , 2020, 8, e000953.		32
132	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 934.e1-934.e9.	0.8	2
133	Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. <i>Cancer</i> , 2020, 126, 4446-4450.	2.0	7
134	Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?. <i>EBioMedicine</i> , 2020, 56, 102812.	2.7	0
135	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 783-785.	0.9	20
136	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , 2020, 26, 1733-1741.	15.2	282
137	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3672-3684.	0.8	78
138	Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors. <i>European Urology</i> , 2020, 78, 498-502.	0.9	108
139	Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices. <i>Journal of Clinical Medicine</i> , 2020, 9, 1508.	1.0	3
140	Physical activity and risk of bladder cancer among postmenopausal women. <i>International Journal of Cancer</i> , 2020, 147, 2717-2724.	2.3	2
141	Sequencing Therapies for Metastatic Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 305-318.	0.8	14
142	Strategies to Improve Participation of Older Adults in Cancer Research. <i>Journal of Clinical Medicine</i> , 2020, 9, 1571.	1.0	16
143	Genomic profiling in renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 435-451.	4.1	99
144	Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. <i>Nature Reviews Urology</i> , 2020, 17, 271-291.	1.9	32

#	ARTICLE	IF	CITATIONS
145	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. <i>Cancer</i> , 2020, 126, 2597-2606.	2.0	39
146	Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Oncologist</i> , 2020, 25, 186-188.	1.9	1
147	Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting—Role of Academic and Hybrid Modeling. <i>Journal of Clinical Medicine</i> , 2020, 9, 1884.	1.0	5
148	Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma. , 2020, 8, e000419.		7
149	Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 800-809.	0.6	12
150	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e543-e556.	0.9	22
151	Urothelial cancer harbours <i>EGFR</i> and <i>HER2</i> amplifications and exon 20 insertions. <i>BJU International</i> , 2020, 125, 739-746.	1.3	14
152	Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100172.	0.7	11
153	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020, 126, 73-82.	1.3	19
154	Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1797-1806.	0.8	102
155	Tivozanib in renal cell carcinoma: a new approach to previously treated disease. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092381.	1.4	10
156	Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: Results from cohort 2 of the COSMIC-021 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5013-5013.	0.8	22
157	Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. <i>JCO Oncology Practice</i> , 2020, 16, e1264-e1271.	1.4	16
158	COVID-19 and androgen-targeted therapy for prostate cancer patients. <i>Endocrine-Related Cancer</i> , 2020, 27, R281-R292.	1.6	64
159	Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 329-354.	2.3	383
160	Biopsychosocial distress and clinical outcome in metastatic renal cell carcinoma. <i>Palliative and Supportive Care</i> , 2019, 17, 353-355.	0.6	7
161	Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. <i>Journal of Geriatric Oncology</i> , 2019, 10, 149-154.	0.5	14
162	Non-invasive diagnosis and monitoring of urothelial bladder cancer: are we there yet?. <i>BJU International</i> , 2019, 124, 361-362.	1.3	0

#	ARTICLE	IF	CITATIONS
163	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. <i>European Urology</i> , 2019, 76, 599-603.	0.9	95
164	Factors that influence the androgen receptor cistrome in benign and malignant prostate cells. <i>Molecular Oncology</i> , 2019, 13, 2616-2632.	2.1	12
165	First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options. <i>Targeted Oncology</i> , 2019, 14, 639-645.	1.7	14
166	Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?. <i>Lancet Oncology, The</i> , 2019, 20, 1473-1474.	5.1	5
167	A phase 1 trial of SGNâ€CD70A in patients with CD70â€positive, metastatic renal cell carcinoma. <i>Cancer</i> , 2019, 125, 1124-1132.	2.0	41
168	Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2019, 20, 1386-1394.	5.1	69
169	First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2019, 2, 708-715.	2.6	64
170	Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. <i>PLoS ONE</i> , 2019, 14, e0210415.	1.1	8
171	Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium. <i>ACS Omega</i> , 2019, 4, 2472-2481.	1.6	16
172	Ideal Glucocorticoid Regimen With Abiraterone Acetate. <i>JAMA Oncology</i> , 2019, 5, 1167.	3.4	0
173	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscleâ€invasive bladder cancer. <i>Cancer</i> , 2019, 125, 3155-3163.	2.0	32
174	Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. <i>BMC Cancer</i> , 2019, 19, 548.	1.1	34
175	Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1780-1782.	0.6	7
176	Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 978-986.	1.3	36
177	Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy. , 2019, 7, 71.		21
178	The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions. <i>Current Treatment Options in Oncology</i> , 2019, 20, 41.	1.3	25
179	Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 11.	1.3	11
180	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2019, 20, 581-590.	5.1	124

#	ARTICLE	IF	CITATIONS
181	Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?. <i>European Urology Oncology</i> , 2019, 2, 365-378.	2.6	47
182	Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19â€“FGFR4â€“KLB Pathway Inhibition. <i>Cancer Discovery</i> , 2019, 9, 1646-1649.	7.7	14
183	Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 711-716.	0.6	2
184	Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2185-2193.	1.9	84
185	Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989028.	1.4	74
186	Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers. <i>JAMA Oncology</i> , 2019, 5, 529.	3.4	192
187	Circulating tumor DNA alterations in patients with metastatic castrationâ€“resistant prostate cancer. <i>Cancer</i> , 2019, 125, 1459-1469.	2.0	38
188	Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. <i>Cancer</i> , 2019, 125, 533-540.	2.0	38
189	The Microbiome and Genitourinary Cancer: A Collaborative Review. <i>European Urology</i> , 2019, 75, 637-646.	0.9	103
190	Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome. <i>Oncologist</i> , 2019, 24, 143-145.	1.9	3
191	Distress in patients with renal cell carcinoma: a curious gap in knowledge. <i>BJU International</i> , 2019, 123, 208-209.	1.3	14
192	Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 101-101.	0.8	75
193	Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4502-4502.	0.8	36
194	Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4504-4504.	0.8	21
195	Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4510-4510.	0.8	7
196	Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4515-4515.	0.8	3
197	Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4524-4524.	0.8	11
198	Interim analysis of the fierce-21 phase 2 (P2) study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4547-4547.	0.8	5

#	ARTICLE	IF	CITATIONS
199	TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2019, 37, 4572-4572.	0.8	1
200	Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development.. Journal of Clinical Oncology, 2019, 37, 4581-4581.	0.8	6
201	A phase III randomized open label study comparing bempedaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, TPS4595-TPS4595.	0.8	3
202	Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2019, 37, 409-409.	0.8	30
203	Androgen Receptor and PI3K Pathway Activity in Ovarian Cancer. , 2019, 1, 1-5.		1
204	Prediction of metastatic castrate-resistant prostate cancer response to abiraterone or enzalutamide by a baseline blood-based CTC gene expression signature.. Journal of Clinical Oncology, 2019, 37, e16529-e16529.	0.8	1
205	Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of metastatic prostate cancer (mPC) patients.. Journal of Clinical Oncology, 2019, 37, 5032-5032.	0.8	0
206	Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivolpi).. Journal of Clinical Oncology, 2019, 37, 4555-4555.	0.8	0
207	Prognostic value of sequential <sup>18</sup> F-FDG + Na <sup>18</sup> F PET/CT (NaF+FDG PET) in metastatic genitourinary (GU) cancer patients (pts) treated with cabozantinib/nivolumab +/- ipilimumab (CaboNivolpi).. Journal of Clinical Oncology, 2019, 37, 4544-4544.	0.8	0
208	Analysis of <i>EGFR</i> mutant urothelial carcinoma (UC) reveals distinct mutational landscape.. Journal of Clinical Oncology, 2019, 37, 4545-4545.	0.8	0
209	Identifying patient-reported anxiety and depression in older adults with cancer.. Journal of Clinical Oncology, 2019, 37, 11556-11556.	0.8	0
210	Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.. Journal of Clinical Oncology, 2019, 37, 4578-4578.	0.8	0
211	NT5E expression and the immune landscape of prostate cancer (PC): An analysis from The Cancer Genome Atlas database.. Journal of Clinical Oncology, 2019, 37, e16591-e16591.	0.8	0
212	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.. Journal of Clinical Oncology, 2019, 37, e16017-e16017.	0.8	0
213	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).. Journal of Clinical Oncology, 2019, 37, 4577-4577.	0.8	1
214	A Support Intervention for Family Caregivers of Advanced Cancer Patients. Journal of the Advanced Practitioner in Oncology, 2019, 10, 444-455.	0.2	6
215	Genomic profiling: Shared decision making and emotional well-being among patients with metastatic genitourinary cancers.. Journal of Clinical Oncology, 2019, 37, 31-31.	0.8	4
216	The Role of Circulating Tumor DNA in Renal Cell Carcinoma. Current Treatment Options in Oncology, 2018, 19, 10.	1.3	34

#	ARTICLE	IF	CITATIONS
217	The androgen receptor malignancy shift in prostate cancer. <i>Prostate</i> , 2018, 78, 521-531.	1.2	24
218	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. <i>Cancer</i> , 2018, 124, 2115-2124.	2.0	79
219	Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 162.e1-162.e6.	0.8	19
220	Current systemic therapies for metastatic renal cell carcinoma in older adults: A comprehensive review. <i>Journal of Geriatric Oncology</i> , 2018, 9, 265-274.	0.5	5
221	Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC). <i>Cancer</i> , 2018, 124, 1216-1224.	2.0	52
222	Comprehensive Genomic Profiling of Renal Cell Carcinoma at Initial Diagnosis and Putative Local Recurrence. <i>European Urology Focus</i> , 2018, 4, 267-269.	1.6	2
223	Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 190-197.	0.5	0
224	<i>HSD3B1</i> A Predictive Biomarker in Advanced Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 562.	3.4	1
225	Lymph node-positive prostate cancer after robotic prostatectomy and extended pelvic lymphadenectomy. <i>Journal of Robotic Surgery</i> , 2018, 12, 425-431.	1.0	6
226	Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile. <i>European Urology</i> , 2018, 73, 308-310.	0.9	12
227	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. <i>Oncoimmunology</i> , 2018, 7, e1380764.	2.1	111
228	Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions. <i>European Urology</i> , 2018, 73, 541-542.	0.9	9
229	Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1-e9.	0.9	11
230	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 757-764.	0.8	43
231	Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	11
232	Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. <i>Oncologist</i> , 2018, 23, 1413-e151.	1.9	11
233	Biomarkers in renal-cell carcinoma: building on clinical paradigms. <i>Lancet Oncology</i> , The, 2018, 19, 1560-1561.	5.1	0
234	STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 5948-5962.	3.2	59

#	ARTICLE	IF	CITATIONS
235	Value-based genomics. <i>Oncotarget</i> , 2018, 9, 15792-15815.	0.8	46
236	NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1041-1053.	2.3	171
237	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 663-669.	2.9	66
238	Assessment of distress and quality of life in rare cancers. <i>Psycho-Oncology</i> , 2018, 27, 2740-2746.	1.0	29
239	Advances in the Treatment of Metastatic Renal Cell Carcinoma. <i>Cancer Treatment and Research</i> , 2018, 175, 127-137.	0.2	6
240	Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer. <i>European Urology</i> , 2018, 74, 239-240.	0.9	0
241	Next Generation Sequencing in metastatic castrate-resistant prostate cancer. <i>Urology Case Reports</i> , 2018, 19, 60-62.	0.1	3
242	Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. <i>European Urology</i> , 2018, 74, 611-620.	0.9	77
243	Efficacy of BCGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations. <i>Cancer Discovery</i> , 2018, 8, 812-821.	7.7	206
244	Cytoreductive nephrectomy: questions remain after CARMENA. <i>Nature Reviews Urology</i> , 2018, 15, 530-532.	1.9	5
245	Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States. <i>Bladder Cancer</i> , 2018, 4, 227-238.	0.2	55
246	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. , 2018, 6, 9.		141
247	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 758-765.	1.6	89
248	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	15.2	900
249	Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma. <i>Case Reports in Oncology</i> , 2018, 11, 276-280.	0.3	11
250	Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1439-1445.	0.5	32
251	Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 124-128.	0.9	52
252	Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. <i>European Urology</i> , 2018, 73, 71-78.	0.9	87

#	ARTICLE	IF	CITATIONS
253	<i>ATM/RB1</i> mutations predict shorter overall survival in urothelial cancer. <i>Oncotarget</i> , 2018, 9, 16891-16898.	0.8	28
254	The role of peroxisome proliferator-activated receptor gamma in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 238.	0.8	39
255	Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2017, 3, 130-135.	1.6	9
256	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 312-322.	5.1	1,388
257	Cytoreductive nephrectomy: A medical oncologistâ€™s perspective. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 180-182.	0.8	0
258	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 557-564.	0.9	108
259	Which checkpoint inhibitor? An embarrassment of riches for bladder cancer. <i>Immunotherapy</i> , 2017, 9, 463-466.	1.0	2
260	Vitamin K epoxide reductase expression and prostate cancer risk. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 112.e13-112.e18.	0.8	4
261	TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. <i>Journal of Leukocyte Biology</i> , 2017, 102, 423-436.	1.5	47
262	Complications After Metastasectomy for Renal Cell Carcinomaâ€”A Population-based Assessment. <i>European Urology</i> , 2017, 72, 171-174.	0.9	44
263	Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma?. <i>European Urology</i> , 2017, 72, 972-973.	0.9	0
264	<i>ALK</i> Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. <i>Oncologist</i> , 2017, 22, 1444-1450.	1.9	81
265	Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. <i>Cancer</i> , 2017, 123, 4566-4573.	2.0	37
266	Sarcomatoid Renal Cell Carcinoma: The Apple Doesn't Fall Far from the Tree. <i>Clinical Cancer Research</i> , 2017, 23, 6381-6383.	3.2	7
267	Recommendations for the Management of Rare Kidney Cancers. <i>European Urology</i> , 2017, 72, 974-983.	0.9	36
268	A step towards predicting checkpoint inhibitor response in kidney cancer. <i>Lancet Oncology</i> , The, 2017, 18, 982-983.	5.1	3
269	The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. <i>Immunotherapy</i> , 2017, 9, 681-692.	1.0	94
270	A phase 2 study of the sphingosineâ€”1-phosphate antibody sonpicipizumab in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2017, 123, 576-582.	2.0	39



#	ARTICLE	IF	CITATIONS
271	Biomarkers in Genitourinary Cancers: Blazing the Path Forward. <i>European Urology</i> , 2017, 71, 247-248.	0.9	2
272	Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice. <i>Kidney Cancer</i> , 2017, 1, 99-105.	0.2	9
273	Exceptional Response to Palbociclib in Metastatic Collecting Duct Carcinoma Bearing a CDKN2A Homozygous Deletion. <i>JCO Precision Oncology</i> , 2017, 1, 1-5.	1.5	11
274	Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2017, 1, 15-29.	0.2	4
275	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3851-3858.	0.8	384
276	Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 337-342.	1.8	19
277	Vitamin K epoxide reductase regulation of androgen receptor activity. <i>Oncotarget</i> , 2017, 8, 13818-13831.	0.8	25
278	Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. <i>Oncotarget</i> , 2017, 8, 33614-33620.	0.8	45
279	IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4505-4505.	0.8	55
280	A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4598-TPS4598.	0.8	23
281	Genomic mutation-driven metastatic breast cancer therapy: a single center experience. <i>Oncotarget</i> , 2017, 8, 26414-26423.	0.8	12
282	Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. <i>Cancer</i> , 2016, 122, 702-711.	2.0	81
283	Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e1025-e1034.	2.5	83
284	Case Discussion: Systemic Therapy for Metastatic Renal Cell Carcinoma. <i>European Urology Focus</i> , 2016, 2, 579-581.	1.6	1
285	Re: Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial. <i>European Urology</i> , 2016, 70, 203.	0.9	1
286	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3655-3663.	0.8	174
287	Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar. <i>Lancet Oncology</i> , The, 2016, 17, 1477-1478.	5.1	2
288	Metastasis in renal cell carcinoma: Biology and implications for therapy. <i>Asian Journal of Urology</i> , 2016, 3, 286-292.	0.5	107

#	ARTICLE	IF	CITATIONS
289	Up-front Targeted Therapy Prior to Cytoreductive Nephrectomy in Treatment-Naive Patients With Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 1273.	3.4	0
290	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 917-927.	5.1	789
291	Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3267-3275.	0.8	185
292	CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 267-275.	1.4	45
293	Finding a niche for girentuximab in metastatic renal cell carcinoma. <i>Nature Reviews Urology</i> , 2016, 13, 442-443.	1.9	9
294	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. <i>European Urology Focus</i> , 2016, 2, 204-209.	1.6	40
295	Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. <i>Oncologist</i> , 2016, 21, 33-39.	1.9	69
296	Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine. <i>European Urology</i> , 2016, 70, 42-44.	0.9	0
297	Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 153-159.	0.9	14
298	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.	0.8	141
299	Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. <i>European Urology</i> , 2016, 70, 348-357.	0.9	111
300	Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1122-1130.	0.8	376
301	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2445-2452.	3.2	193
302	Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. <i>European Urology</i> , 2016, 70, 516-521.	0.9	90
303	Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancer. <i>Onc Immunology</i> , 2016, 5, e1078060.	2.1	7
304	Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. <i>Oncotarget</i> , 2016, 7, 52442-52449.	0.8	6
305	Novel approaches in cancer immunotherapy – a light at the end of the tunnel. <i>Discovery Medicine</i> , 2016, 21, 479-87.	0.5	3
306	Renal cell carcinoma: An update for the practicing urologist. <i>Asian Journal of Urology</i> , 2015, 2, 19-25.	0.5	10

#	ARTICLE	IF	CITATIONS
307	Circulating tumor cells in prostate cancer: Does (nuclear) size matter?. <i>Cancer</i> , 2015, 121, 3190-3192.	2.0	0
308	A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for <i>Agaricus bisporus</i> -induced prostate-specific antigen responses. <i>Cancer</i> , 2015, 121, 2942-2950.	2.0	44
309	Cabazitaxel for the therapy of metastatic castration-resistant prostate cancer in the aftermath of the <sc>CHAARTED</sc> trial. <i>BJU International</i> , 2015, 116, 839-840.	1.3	0
310	Conditional Survival in de novo Metastatic Urothelial Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0136622.	1.1	12
311	TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3771-3782.	3.2	152
312	Metastatic renal cell carcinoma: Contending with a sea change in therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 507-508.	0.8	8
313	Pazopanib as Third Line Therapy for Metastatic Renal Cell Carcinoma: Clinical Efficacy and Temporal Analysis of Cytokine Profile. <i>Journal of Urology</i> , 2015, 193, 1114-1121.	0.2	25
314	Detection and Phenotyping of Circulating Tumor Cells in High-Risk Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 130-136.	0.9	45
315	RNA-seq Reveals Aurora Kinase-Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2015, 13, 130-137.	1.5	38
316	Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 178-184.	0.9	15
317	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e79-e85.	0.9	78
318	PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 257-260.	0.9	2
319	Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification. <i>European Urology</i> , 2015, 68, 168-170.	0.9	28
320	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2015, 16, 293-300.	5.1	299
321	SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1601-1608.	0.8	44
322	A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 3420-3427.	3.2	31
323	Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation. <i>European Urology</i> , 2015, 67, 1195-1196.	0.9	20
324	Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation. <i>European Urology</i> , 2015, 68, 341-343.	0.9	4

#	ARTICLE	IF	CITATIONS
325	Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. <i>Cancer</i> , 2015, 121, 2586-2593.	2.0	155
326	Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 517-527.	0.8	16
327	Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2015, 21, 5286-5293.	3.2	52
328	CD8 <sup>+</sup> T cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation. <i>European Journal of Immunology</i> , 2015, 45, 71-81.	1.6	26
329	Development of PROSTVAC immunotherapy in prostate cancer. <i>Future Oncology</i> , 2015, 11, 2137-2148.	1.1	31
330	Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2896-2900.	1.9	15
331	TLR9 signaling through NF- $\kappa$ B/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells. <i>Oncotarget</i> , 2015, 6, 17302-17313.	0.8	53
332	Radium-223 in metastatic castration resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 348.	0.8	12
333	Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future. <i>Oncologist</i> , 2014, 19, 851-859.	1.9	57
334	Preoperative Androgen Deprivation Therapy for Localized Prostate Cancer: Delayed Biochemical Recurrence in High-Risk Disease. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 149-154.	0.9	5
335	Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. <i>European Urology</i> , 2014, 65, 577-584.	0.9	207
336	The dark side of Toll-like receptor signaling. <i>Oncolmmunology</i> , 2014, 3, e27894.	2.1	8
337	Ramucirumab in metastatic renal cell carcinoma: The beginning or the end?. <i>Cancer</i> , 2014, 120, 1604-1607.	2.0	2
338	The best fit for enzalutamide in metastatic prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 504-506.	12.5	3
339	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. <i>European Urology</i> , 2014, 65, 1086-1092.	0.9	71
340	CKD-EPI and Cockcroft-Gault Equations Identify Similar Candidates for Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. <i>PLoS ONE</i> , 2014, 9, e94471.	1.1	7
341	Management of localized prostate cancer: the pendulum swings (back to the middle). <i>Asian Journal of Andrology</i> , 2014, 16, 570.	0.8	1
342	Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , 2013, 119, 2999-3006.	2.0	189

#	ARTICLE	IF	CITATIONS
343	Differentiating mTOR inhibitors in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2013, 39, 709-719.	3.4	85
344	A "Game of Thrones" in Metastatic Renal Cell Carcinoma: Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors and Mammalian Target of Rapamycin Inhibitors Battling for Position. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 1-4.	0.9	8
345	Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: A retrospective analysis†. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1826-1831.	0.8	19
346	Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Tumor: Clinical Outcome and Quality of Life in Long-Term Survivors. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 121-127.	0.9	7
347	A New Age for Vaccine Therapy in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2013, 19, 365-370.	1.0	18
348	Enzalutamide for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 679-685.	0.9	18
349	Optimizing Systemic Therapy for Bladder Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 793-804.	2.3	23
350	Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era. <i>PLoS ONE</i> , 2013, 8, e63341.	1.1	62
351	Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 146-55.	0.3	15
352	Prolonged Therapy With Cabazitaxel in an Octogenarian With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 274-276.	0.9	3
353	Retrospective Analysis of Clinical Outcomes With Neoadjuvant Cisplatin-Based Regimens for Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 246-250.	0.9	27
354	Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 583-591.	0.8	5
355	Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer. <i>BMC Cancer</i> , 2012, 12, 435.	1.1	20
356	Tivozanib: current status and future directions in the treatment of solid tumors. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1851-1859.	1.9	12
357	Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 526-537.	1.9	39
358	S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites. <i>Cancer Cell</i> , 2012, 21, 642-654.	7.7	229
359	Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults. <i>Drugs and Aging</i> , 2011, 28, 635-649.	1.3	16
360	Managing Refractory Metastatic Renal Cell Carcinoma: A RECORD Spinning on a Tilted AXIS. <i>Clinical Genitourinary Cancer</i> , 2011, 9, 3-5.	0.9	2

#	ARTICLE	IF	CITATIONS
361	Triple negative breast cancer: unmet medical needs. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 627-636.	1.1	279
362	Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. <i>Targeted Oncology</i> , 2011, 6, 5-16.	1.7	15
363	Unraveling the Role of Hypoxia-Inducible Factor in Renal Cell Carcinoma: A Biological and Therapeutic Perspective. <i>Cancer Discovery</i> , 2011, 1, 198-199.	7.7	0
364	Current paradigms and Evolving concepts in metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2011, 13, 683-689.	0.8	7
365	Mammalian Target of Rapamycin, Akt, and Phosphatidylinositol 3-Kinase Signaling. <i>Journal of Thoracic Oncology</i> , 2010, 5, S487-S489.	0.5	3
366	Targeted therapies for renal cell carcinoma: understanding their impact on survival. <i>Targeted Oncology</i> , 2010, 5, 131-138.	1.7	16
367	Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 25-32.	1.1	15
368	Papillary carcinoma of the breast: an overview. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 637-645.	1.1	97
369	Evaluating the Older Patient with Cancer: Understanding Frailty and the Geriatric Assessment. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 120-132.	157.7	220
370	Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors. <i>Clinical Medicine Insights: Oncology</i> , 2010, 4, CMO.S1590.	0.6	13
371	Critical appraisal of cabazitaxel in the management of advanced prostate cancer. <i>Clinical Interventions in Aging</i> , 2010, 5, 395.	1.3	31
372	Targeted Therapies for Non-Small Cell Lung Cancer: An Evolving Landscape. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1931-1944.	1.9	74
373	Breaking through a Plateau in Renal Cell Carcinoma Therapeutics: Development and Incorporation of Biomarkers. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3115-3125.	1.9	24
374	Akt inhibitors in clinical development for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1355-1366.	1.9	202
375	Deciphering the anticancer mechanisms of sunitinib. <i>Cancer Biology and Therapy</i> , 2010, 10, 712-714.	1.5	5
376	Renal cell carcinoma therapy in 2010: many options with little comparative data. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 191-200.	0.3	7
377	Adjuvant Chemotherapy for Older Adults with Breast Cancer: Making the Standard a Standard. <i>Women's Health</i> , 2009, 5, 481-484.	0.7	2
378	Adjuvant Systemic Therapy for Older Adults with Early-Stage Breast Cancer. <i>Women's Health</i> , 2009, 5, 251-262.	0.7	3

#	ARTICLE	IF	CITATIONS
379	An association between invasive breast cancer and familial idiopathic hyperparathyroidism: a case series and review of the literature. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 1-5.	1.1	9
380	Triple-negative breast cancer: Novel therapies and new directions. <i>Maturitas</i> , 2009, 63, 269-274.	1.0	49
381	Beyond castration and chemotherapy: Novel approaches to targeting androgen-driven pathways. <i>Maturitas</i> , 2009, 64, 61-66.	1.0	5
382	The Role of Targeting Mammalian Target of Rapamycin in Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, 340-345.	1.1	42
383	Patient-Reported Outcomes in Early Phase Clinical Trials: An Opportunity to Actively Promote Patient-Centered Care. <i>Oncologist</i> , 0, , .	1.9	3